Protalix is a biopharmaceutical company that develops treatments for rare and orphan diseases using ProCellEx, its proprietary plant cell-based protein expression platform, which enables the production of complex recombinant proteins at commercial scale. The company markets two FDA-approved enzyme replacement therapies: Elelyso for Gaucher disease (commercialized globally through Pfizer) and Elfabrio for Fabry disease (commercialized through Chiesi), generating revenue primarily through B2B supply agreements with these partners who handle marketing and distribution. Protalix also operates a clinical pipeline including PRX-115 for gout and PRX-119 for NET-related diseases, supported by its proprietary manufacturing facility in Israel and a patent portfolio covering its production methodologies and product candidates.